Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.34 |
| ▸ | XIAP | P98170 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3536340 | 0.97 | GAA (0.37) | GAAADRB3XIAPKMT2A | |
| SCHEMBL13314792 | 0.97 | GAA (0.37) | GAAADRB3XIAPKMT2A | |
| Formic Acid SCHEMBL3540804 | 0.86 | XIAP (0.35) | ADRB3XIAP | |
| Formic Acid SCHEMBL3537717 | 0.83 | XIAP (0.38) | GAAADRB3XIAP | |
| Formic Acid SCHEMBL3544409 | 0.83 | F2 (0.41) | GAAADRB3XIAP | |
| Formic Acid SCHEMBL3537792 | 0.82 | KRAS (0.46) | ADRB3XIAP | |
| SCHEMBL13314796 | 0.81 | XIAP (0.37) | ADRB3XIAP | |
| SCHEMBL3542684 | 0.81 | XIAP (0.37) | ADRB3XIAP | |
| Formic Acid SCHEMBL3542174 | 0.80 | NOS1 (0.31) | — | |
| SCHEMBL3541027 | 0.79 | XIAP (0.40) | GAAADRB3XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7727979-B2 | Guanidine derivatives and their use as neuropeptide FF receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-06-01 | — | — | US | disclosed |
| US-20060194788-A1 | Guanidine derivatives and their use as neuropeptide ff receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2006-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194788-A1 | Guanidine derivatives and their use as neuropeptide ff receptor antagonists | NPFFR1, OGFR, NPFFR2 | GAA 1530/4885ADRB3 144/4885XIAP 3138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.